- mg/kg subcutaneously once a day
-Safety and effectiveness in pediatric patients with HIV have not been established.
-Somatropin clearance appears similar in adults and children, but no pharmacokinetic studies have been conducted in children with HIV.
-Two small studies (total of 16 patients) of up to 26 weeks duration showed therapy was well tolerated with safety observations consistent with the adult studies.
Use: Treatment of HIV patients with wasting or cachexia to increase lean body mass and body weight, and improve physical endurance